Immunosuppression and SARS-CoV-2 Infection in Kidney Transplant Recipients

Arnaud Devresse, MD, PhD,1,2 Julien De Greef, MD,2,3 Jean Cyr Yombi, MD,2,3 Leila Belkhir, MD, PhD,2,3 Eric Goffin, MD,1,2 and Nada Kanaan, MD1,2

Abstract. Kidney transplant recipients (KTRs) infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) may have an increased risk of mortality compared with the general population and hemodialysis patients. As these patients are immunosuppressed, it might seem obvious to attribute this excess mortality to the impaired immunity induced by immunosuppression. In line with this reasoning is the low immune response, both cellular and humoral, that KTRs mount in response to the anti–SARS-CoV-2 vaccine; however, acute respiratory distress syndrome associated with coronavirus disease 2019 is triggered by a state of inflammation and cytokine release syndrome that lead to pulmonary damage and increased mortality. In that context, immunosuppressive treatment dampening the immune response could, in theory, be potentially beneficial. This review aims at analyzing the current knowledge on the impact of immunosuppressive treatment on mortality in SARS-CoV-2–infected KTRs, the optimal management of immunosuppression in the coronavirus disease 2019 era, and the vaccine response and management in immunosuppressed KTRs.

(Transplantation Direct 2022;8: e1292; doi: 10.1097/TXD.0000000000001292)

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has shaken the world since its initial outbreak in December 2019. As of November 2021, >261,000,000 cases and 5,200,000 deaths have been reported by the World Health Organization, and the numbers continue to rise.1 Mortality rates by country—provided by the Johns Hopkins University—range from 0.1% to 9.2% with important geographic variations.2

Kidney transplant recipients (KTRs) infected with SARS-CoV-2 have shown increased death rates. Indeed, data derived from 3 meta-analyses demonstrated mortality rates ranging from 18.6% to 23%, respectively.3-5 Moreover, in a multivariate analysis for predictors of mortality in 10,926 coronavirus disease 2019 (COVID-19)–related deaths in England, solid organ transplant (SOT) recipients had the highest hazard ratio of 3.53 (95% confidence interval, 2.77-4.49) compared with hazard ratio of other infected patients including those with comorbidities such as cancer, hematological malignancy, chronic respiratory disease, rheumatoid diseases, and so on.6 A nationwide cohort in Denmark showed similar results7; however, these studies do not allow us to accurately define the increased mortality rate in KTRs, as SOT recipient groups were heterogeneous and the exact number of KTRs included was not reported. As patients undergoing transplantation receive immunosuppressive treatment to prevent rejection, it might seem obvious to attribute the excess mortality encountered by KTRs infected with SARS-CoV-2 to the impaired immunity secondary to immunosuppression. In line with this reasoning is the lower immune response, both cellular and humoral, that KTRs mount in response to the anti–SARS-CoV-2 vaccine8-10; however, complications associated with SARS-CoV-2 infection—mainly acute respiratory distress syndrome (ARDS)—are triggered by a state of dysregulated inflammation and cytokine release syndrome that lead to pulmonary damage and increased mortality.11-13 In that context, immunosuppressive treatment dampening the immune response could be potentially beneficial.

This review aims at analyzing the current knowledge on (1) the impact of immunosuppressive treatment on mortality, (2) the optimal management of immunosuppression in the COVID-19 era, and (3) the vaccine response and management in immunosuppressed KTRs.

Impact of Immunosuppression on Mortality From COVID-19 Infection in KTRs

Studies from Europe, England, United States, Canada, and South America have reported a mortality rate ranging...
from 20% to 32% in KTRs compared with 1% to 14% in the general population, after adjustment for age and comorbidities. \(^{14-23}\) When compared with hemodialysis patients, the mortality of KTRs also seems higher.\(^ {15,17}\) Increased mortality in KTRs may indirectly suggest a negative impact of immunosuppression. Indeed, both innate and adaptive immunity are activated following SARS-CoV-2 infection and are necessary to clear the virus.\(^ {24,25}\) Immunosuppressive agents given after KT affect both innate and adaptive immunity and might impair the immune control of the viral replication.\(^ {26}\) In favor with this assumption, a Spanish national study\(^ {27}\) reported that a SARS-CoV-2 infection occurring in the first 60 d after KT—when the immunosuppressive burden is the most intense—was associated with a significantly increased mortality rate of 45.8%. In agreement with this finding, a report from the European Renal Association COVID-19 Database comparing mortality in KTRs and hemodialysis patients showed that, in a fully adjusted model for age, sex, frailty, and comorbidities, the risk of mortality was higher in KTRs and increased during the first posttransplant year, without, however, association between immunosuppressive treatments and mortality.\(^ {17}\) A large Brazilian multicenter cohort study including 1680 SARS-CoV-2–infected KTRs (65.1% requiring hospitalization) reported a 90-d death rate of 21%.\(^ {28}\) In the multivariate analysis, the use of tacrolimus (Tac) and mycophenolic acid (MPA)—the most commonly used immunosuppressive combination\(^ {29}\)—was independently associated with the risk of death. Although these studies indirectly suggest an impact of immunosuppression, others have failed to demonstrate differences in the outcome between patients transplanted <1 y ago and those transplanted for a longer time,\(^ {26}\) as well as patients receiving induction therapy with lymphocyte depleting agents versus nondepleting agents,\(^ {16}\) suggesting that the degree of immunosuppression does not have a major impact on disease severity and outcome.\(^ {30}\) Moreover, a cytokine release syndrome—arising from an inadequate immune response implicating interleukins, the complement, and intense antibody response to the virus—has been identified as responsible for negative outcomes of pneumonia, in which case immunosuppressive agents, including calcineurin inhibitors (CNIs), MPA, and glucocorticoids, could also theoretically be beneficial.\(^ {31}\) In fact, glucocorticoids are currently one of the treatments to have proven efficacy in patients admitted for severe COVID-19 pneumonia.\(^ {32}\) To delineate the role of comorbidities versus immunosuppression on mortality rates, recent studies have compared KTRs infected with COVID-19 to nontransplanted patients with similar comorbidities. Chaudhry et al\(^ {33}\) first showed a similar rate of mortality, need of intensive care unit, and mechanical ventilation support in COVID-19 hospitalized SOT recipients compared with nontransplant controls, suggesting that the transplant status by itself does not confer an increased predictive risk of mortality or severe disease. More recently, studies comparing the clinical outcomes of COVID-19 in patients with SOT to a propensity-matched cohort of nontransplanted patients with similar comorbidities showed similar severity of infection and mortality.\(^ {18-20,34}\) These studies conclude that long-term immunosuppression does not seem to increase the risk of developing severe forms of COVID-19; however, it must be underlined that in almost all studies, immunosuppression was decreased when KTRs were hospitalized, although in a nonhomogeneous way. Tables 1 and 2 summarize the main studies—including at least 100 KTRs—that have compared the outcomes of COVID-19 in KTRs versus matched control groups. It is worth noting that the high heterogeneity of these studies in terms of patients included (SOT recipients versus KTRs alone), study design, type, and selection of the control group, and periods of inclusions is most likely one of the main explanations for the contrasting conclusions.

### TABLE 1

**Studies (including at least 100 transplanted patients) showing an increased death rate in transplanted patients vs controls**

| Publications | Country | Time of inclusion | Population study | Control group | Main findings |
|--------------|---------|-------------------|------------------|---------------|--------------|
| Goffin et al\(^ {17}\) | Europe — ERACODA database | February 1–December 1, 2020 | 496 KTRs | -1174 hemodialysis patients | -In a fully adjusted model, the risk was 78% higher in KTRs (HR, 1.78; 95% CI, 1.22-2.61) than in hemodialysis patients. |
| Fisher et al\(^ {22}\) | United States | March 10–September 1, 2020 | 128 hospitalized SOT recipients | Hospitalized immunocompetent general population (multicenter retrospective cohort study, \(n = 38,944\)) Coarsened exact matched control cohort: 3907 | -This association was similar in patients tested because of symptoms (fully adjusted model: HR, 2.00; 95% CI, 1.31-3.06). -This risk was dramatically increased during the first posttransplant year. -Patients with a history of SOT were more likely to die within the study period than matched non-SOT recipients (21.9% and 14.9%, respectively; OR, 1.93; 95% CI, 1.18-3.1). |
| Caillard et al\(^ {23}\) | France | March 1–April 30, 2020 | 306 hospitalized KTRs | Hospitalized immunocompetent general population (single-center retrospective cohort study, \(n = 795\)) Matched for age and risk factors for severe COVID-19 or mortality | -Thirty-day COVID-19–related mortality was significantly higher in KTRs (17.9% vs 11.4%, respectively, \(P = 0.038\)). |

CI, confidence interval; COVID-19, coronavirus disease 2019; ERCODA, European Renal Association COVID-19 Database; HR, hazard ratio; KTR, kidney transplant recipient; OR, odds ratio; SOT, solid organ transplant.
Thus, at the current moment, although immunosuppression is a heavy contributor to the comorbidities affecting KTRs that make them at risk of complications and fatal outcome, it is still unclear whether immunosuppression by itself leads to an increased mortality in KTRs.

Management of Immunosuppression in SARS-CoV-2–infected KTRs: Guidelines and Uncertainties

Lowering immunosuppression—especially antimetabolite drugs—in case of symptomatic SARS-CoV-2 infection has been applied by most KT centers. Table 3 summarizes the main guidelines available regarding the management of immunosuppression in SARS-CoV-2–infected KTRs.

However, because randomized data are lacking, the optimal strategy of immunosuppression reduction, as well as its safety and efficacy, is not well defined. Immunosuppression minimization seems logical to unleash the antiviral T-cell response to control the infection. In contrast, maintaining baseline immunosuppression is also a reasonable approach to mitigate the development of an uncontrolled overactivation of the immune response that is associated with the development of ARDS. A randomized controlled trial comparing maintenance versus reduction of immunosuppression (NCT04420364) has been set up, but inclusions were terminated early because of lack of recruitment.

Safety concerns also exist on the middle- and long-term immunological consequences of immunosuppression minimization. Indeed, in other settings, as in BK virus infection, a prolonged and intense minimization has been associated with an increased risk of developing de novo donor-specific antibodies (DSAs). Little is known about the potential risk of DSA development after COVID-19.

TABLE 2. Studies (including at least transplanted 100 patients) showing similar death rates in transplanted patients vs controls

| Publications       | Country     | Time of inclusion | Population study | Control group | Main findings                                                                 |
|--------------------|-------------|-------------------|------------------|---------------|------------------------------------------------------------------------------|
| Chavarot et al18   | France      | February 26–May 22, 2020 | 100 hospitalized KTRs | -Hospitalized immunocompetent general population (multicenter retrospective cohort study, n = 2878) | -Similar survival between KTRs and matched nontransplant patients with respective 30-d survival of 62.9% and 71% (P = 0.38) |
| Mamode et al20     | United Kingdom | March–April 2020 | 121 hospitalized KTRs | -Propensity score matched (1:1) | -Similar mortality rates (30%) in KTRs vs 27% in controls, P = 0.71 |
| Pereira et al21    | United States | March 10–May 30, 2020 | 117 hospitalized SOT recipients (56% of KTRs) | -Hospitalized immunocompetent general population (single-center retrospective cohort study, n = 2714) | -Mortality (23.08% in SOT recipients vs 23.14% in controls, P = 0.21) was similar in both groups |
| Hadi et al19       | United States | January 20–September 30, 2020 | 2307 SOT recipients (75% of KTRs), 715 requiring hospitalization | -Propensity score matched (3:1) | -No difference in mortality at 30 d (6.45% vs 5.29%; RR, 1.22; 95% CI, 0.88–1.68) or 60 d postdiagnosis (RR, 1.05; 95% CI, 0.83–1.32) |

CI, confidence interval; KTR, kidney transplant recipient; RR, relative risk; SOT, solid organ transplant.

TABLE 3. Guidelines regarding management of immunosuppression in COVID-19 KTRs

| Guidelines          | Key recommendations                                                                 |
|---------------------|----------------------------------------------------------------------------------------|
| TTS40               | -No strong recommendation                                                               |
| ERA37               | -Calibration of dose reduction has to be balanced with the risk of acute rejection      |
| AST34               | -Maintain IS treatments unchanged in KTRs <60 y without pulmonary infiltrates.         |
| BTS34               | -In all other cases, MPA should be stopped, as well as CNI and mTORi if concomitant fever or hypoxia |
| FST41               | -Consider immunosuppression reduction                                                  |
|                   | -Stop antiproliferative agents, and consider CNI reduction                              |
|                   | -Nonhospitalized patients: 50% reduction of antimetabolite dose (or complete withdrawal on case-by-case basis), stop mTORi, maintain CNI doses (T0 Tac 4–7 ng/mL, T0 Csa 50–125 ng/mL) and steroids, and stop belatacept in acute phase of the disease |
|                   | -Hospitalized patients (without ARDS): stop antimetabolite, mTORi, belatacept, maintain steroids, and CNI (T0 Tac 4–6 ng/mL, T0 Csa 50–75 ng/mL) |
|                   | -ARDS: just maintain steroids                                                           |
|                   | -After clinical recovery: consider IS increasing                                        |

AST, American Society of Transplantation; ARDS, acute respiratory distress syndrome; BTS, British Transplant Society; CNI, calcineurin inhibitor; COVID-19, coronavirus disease 2019; Csa, cyclosporine A; ERA, European Renal Association; FST, French Society of Transplantation; IS, immunosuppression; KTR, kidney transplant recipient; MPA, mycophenolic acid; mTORi, mechanistic target of rapamycin; Tac, tacrolimus; TTS, The Transplant Society.
of 17 d. Up to 3 mo after discharge, no rejection episode or emergence of de novo DSAs were observed, and no significant changes occurred in the calculated panel reactive antibodies. Nevertheless, longer follow-up studies with larger cohorts are necessary to assess the safety of minimization strategies.

**Immunosuppressive Drugs and COVID-19: Harmful or Potential Adjuvant Therapy?**

A triphasic course in COVID-19 disease has been described. In the first phase, patients have mild symptoms, such as dry cough, malaise, and fever. An adequate response of the innate and adaptive immune systems can eliminate the virus and preclude disease progression to the next stages. In the second phase, viral multiplication and localized inflammation of the lung tissue occur, causing viral pneumonia. A minority of patients with COVID-19 will undergo a transition to the third and most severe phase of illness: a syndrome of systemic hyper-inflammation, also referred to as the cytokine storm syndrome, associated with high levels of proinflammatory cytokines release, such as interleukin (IL)-2, IL-6, IL-7, and tumor necrosis factor-alpha. In this phase, patients can develop ARDS and multiorgan failure, which are the main causes of death.

In vitro investigations show that some immunosuppressive drugs have antiviral effects against coronaviruses. How immunosuppressive drugs commonly used after KT can potentially affect COVID-19 is discussed below.

**Corticosteroids**

Corticosteroids are widely used after KT. They have a wide range of anti-inflammatory and immunomodulatory effects, including inhibition of the synthesis of proinflammatory cytokines, reduction of leukocyte trafficking, and induction of T-lymphocytes apoptosis. They impair innate, T-cell, and humoral immunity.

Corticosteroids have been tested in immunocompetent patients infected by SARS-CoV-2 in at least 8 cohort studies and 1 open-label randomized trial. Six cohort studies showed that steroid use was associated with a better clinical outcome in patients with COVID-19. However, 2 cohort studies reported opposite results. They found that steroid use was associated with a higher risk of blood stream infections and a lower remission rate. These conflicting results may have resulted from selection bias because of nonrandomization. The RECOVERY trial was an open-label controlled study comparing dexamethasone versus standard of care in hospitalized COVID-19 patients. It showed that dexamethasone was associated with reduced 28-d mortality in patients requiring oxygen supplementation. Effectiveness of steroids in severe COVID-19 was also demonstrated in a meta-analysis. Since then, dexamethasone has been the standard of care in patients with COVID-19 requiring supplemental oxygen; however, as KTRs were excluded from most studies—including RECOVERY—the benefit of increasing steroids in KTRs with symptomatic COVID-19 is still to be proven.

**CNIs**

CNIs—Tac and cyclosporine A—are the cornerstone of most immunosuppressive regimens used after KT. They impact innate, cell-mediated, and humoral immunity. In vitro studies suggest that CNIs have antiviral effects on coronaviruses. Cyclosporine A has been shown to inhibit the replication of several coronaviruses in vitro at nontoxic concentrations and independently of its immunosuppressive effect. A genome-wide analysis of protein–protein interactions between SARS-CoV (SARS-CoV-1) and human host proteins identified FK506 (Tac)-binding proteins as one of the interaction partners for SARS-CoV proteins. In addition, both FK506 treatment and knock down of FK506-binding proteins 1A and 1B inhibited SARS-CoV replication in vitro. Finally, cyclophilins, the binding proteins of cyclosporine A, catalyze the cis/trans isomerization of propyl peptide bonds. This is an essential step in the correct folding of proteins, such as cellular and viral proteins. This function of cyclophilin is found to be important for the replication of SARS-CoV-2.

However, there is no clinical evidence supporting that CNIs may improve the clinical outcomes of COVID-19 in KTRs or in the general population. There is also no evidence that reducing or interrupting CNIs improve the clinical outcome of SARS-CoV-2–infected KTRs. A phase 2 clinical trial is ongoing to test the efficacy of conversion from Tac to voclosporin—a third-generation CNI—to reduce the time of viral clearance in SARS-CoV-2–infected KTRs with mild to moderate symptoms on dual immunosuppressive treatment of steroids and Tac. Current recommendations regarding management of CNI consider reducing doses or drug cessation depending on the severity of the infection (Table 3).

**Antimetabolites**

MPA and azathioprine are the most commonly used antimetabolites after KT. Both drugs inhibit purine synthesis, affecting T- and B-cell proliferation. MPA was shown to inhibit viral replication of 4 different coronaviruses (but not SARS-CoV-2) in cell culture. One in vitro study found that MPA inhibits SARS-CoV-2 replication in VeroE6/TMPRSS2 cells. In another study, human pluripotent stem cells were differentiated into lung organoids and then infected with SARS-CoV-2. In these lung organoids, MPA inhibited viral replication of SARS-CoV-2. To the best of our knowledge, there are no data about azathioprine.

Most guidelines recommend considering MPA cessation in KTRs presenting symptomatic COVID-19. In a large multicenter cohort study of SARS-CoV-2–infected KTRs in Brazil, MPA, when associated with Tac, was an independent risk factor of mortality; however, there is currently no strong clinical evidence showing that MPA interruption modifies the outcome of patients.

**Mechanistic Target of Rapamycine Inhibitors**

Sirolimus and everolimus are inhibitors of the mechanistic target of rapamycin (mTORi). They inhibit protein synthesis, cell cycle progression, and cell growth, impacting mostly innate and cell-mediated immunity. The use of mTORi after KT is associated with a reduced incidence of several viral infections, such as cytomegalovirus and BK virus. mTORi’s were shown to inhibit MERS-CoV replication in vitro. A work based on network drug repurposing suggested sirolimus as a potential treatment for COVID-19. At least 3 clinical trials are ongoing (NCT04341675, NCT04461340, and NCT0498203) to evaluate the effectiveness of mTORi initiation in the general population hospitalized for COVID-19. In KTRs, mTORi did not emerge as protective against the development of severe COVID-19 outcomes; however, it is important to keep in mind that these drugs were interrupted most of the time in hospitalized KTRs with severe diseases.
by fear of their potential negative impact on the pulmonary involvement associated with COVID-19.

**Tocilizumab**

Tocilizumab, an anti–IL-6 receptor, has shown promising results in the treatment of active and chronic antibody-mediated rejection in KTRs. IL-6 is an important proinflammatory cytokine involved in the acute phase response and differentiation and function of B and T cells. IL-6 is also an important actor in the cytokine storm associated with severe forms of COVID-19. Consequently, tocilizumab has been investigated in COVID-19 patients in several cohort studies and a phase 3 placebo-controlled trial. In 3 cohort studies, tocilizumab use was associated with lower mortality and intensive care unit admission rates; however, other cohort studies reported contradictory results. A phase 3 placebo-controlled trial showed that tocilizumab treatment in patients hospitalized with COVID-19 pneumonia was effective to improve a composite end point including mechanical ventilation initiation or death by day 28; however, in another phase 3 placebo-controlled trial, tocilizumab was not superior to the placebo to improve clinical status in patients hospitalized for severe COVID-19. Finally, a meta-analysis showed that tocilizumab was superior to usual care or the placebo to improve a composite end point of progression to mechanical ventilation, extracorporeal membrane oxygenation, or death. Nevertheless, the effectiveness of tocilizumab to improve mortality alone has still to be demonstrated. Small case series suggest that tocilizumab might be used safely with moderate efficacy in COVID-19 KTRs. Pereira et al showed in a case series of 29 hospitalized SOT recipients with severe COVID-19 that tocilizumab could be used safely but was not associated with decreased incidence of 90-d mortality compared with a matched cohort of SOT recipients who did not receive the drug.

**Other Immunosuppressive Drugs**

Induction immunosuppression at KT typically consists of basiliximab or thymoglobulin. Thymoglobulin is a T-cell–depleting agent, especially used in sensitized recipients. Basiliximab is a CD25 receptor antagonist. Thymoglobulin has been associated with an increased risk of viral infection—cytomegalovirus and BK virus—compared with basiliximab. There are currently no published data about the impact of induction therapy on COVID-19. The TANGO trial reported the outcomes of 144 KTRs hospitalized for COVID-19 and did not find a significant difference between KTRs who received induction therapy with lymphocyte depleting agents versus those who did not.

Rituximab, a monoclonal anti-CD20 antibody, is commonly used in HLA- or ABO-incompatible KTs or as treatment of antibody-mediated rejection. A French multicenter cohort study recently showed that treatment with rituximab in patients with inflammatory rheumatic and musculoskeletal diseases was associated with more severe COVID-19; however, published data on KTRs treated with rituximab are lacking.

Belatacept inhibits T-cell activation through costimulation blockade, allowing a CNI-free regimen. Its impact on the risk of developing severe COVID-19 infection has not been well evaluated so far. Although some authors have suggested that belatacept might mitigate the cytokine storm, resulting in a mild form of COVID-19 in KTRs, evidence is very weak and not currently tested in clinical trials. The French Society of Transplantation recommends belatacept cessation in KTRs infected with SARS-CoV-2 (Table 3).

**Immunosuppression and Anti–SARS-CoV-2 Vaccines**

Great hopes were placed in the early vaccination of all immunocompromised patients to reduce the rate of severe forms of COVID-19; however, disappointing results emerged from KTR cohort studies regarding the humoral response rates after 2 doses of mRNA vaccines that ranged from 29.9% to 54% (Table 4). These results contrast with the robust humoral response rates observed in the general population and also in chronic dialysis populations. Cellular response rates were also low. Bertrand et al showed a 57.8% T-cell response rate in 26 KTRs after 2 doses of the BNT162b2 vaccine, using an ELISPOT immunoassay. Cucchiari et al demonstrated a 54.7% T-cell response rate after the second dose of the mRNA-1273 vaccine in 117 SARS-CoV-2–naive transplant patients, also using an ELISPOT immunoassay. We recently reported a cellular response rate of 32.2% (Interferon-Gamma-Release-Assay test) in a cohort of 90 SARS-CoV-2–naive KTRs 1 mo after the second dose of the mRNA BNT162b2 vaccine. Case series of severe SARS-CoV-2 infections in fully vaccinated KTRs have been reported. A recent large multicenter study showed that compared with 101 million fully vaccinated adults in the United States, fully vaccinated SOT recipients (n = 18.215) had an 82-fold higher risk of breakthrough infection and 485-fold higher risk of breakthrough infection with associated hospitalization and death. These data emphasize the importance of the adaptive immune response in the defense against the virus. Regarding such poor results, a third dose of mRNA vaccine was tested in a case series and 1 randomized trial and resulted in a substantial increase of humoral response rates at around 70% (Table 4). Nevertheless, a nonnegligible proportion of KTRs remains with no humoral response even after 3 doses.

Risk factors affecting the humoral response rates after 2 and 3 doses of mRNA vaccine have been suggested from cohort studies (Table 4). The use of MPA seems to be associated with poor response rates. Although not very surprising, as it has already been reported for other vaccines such as influenza, it is a challenging problem because MPA is widely used in KTRs.

Scarce data exist on the impact of other immunosuppressive drugs on the response rate after vaccination. A French group recently reported a low rate of humoral response rates at 6.4% after 3 doses of mRNA vaccine in KTRs treated with belatacept. Also, patients treated with rituximab for rheumatic disease show very low humoral response rate after vaccination. A group of experts of antineutrophil cytoplasmic antibodies vasculitis recently suggested a time window of at least 6 mo between rituximab administration and anti–SARS-CoV-2 vaccination. To the best of our knowledge, there is no formal recommendation in the KT field. Mechanistic targets of rapamycin were reported to increase the humoral response after pneumococcal, tetanus, and influenza vaccines, as they increase CD8+ effector memory T cells; however, the potential positive impact of mTORi on the COVID-19 vaccine-induced humoral response rate has yet to be translated into clinical data.

Less is known regarding the clinical effectiveness of vaccine in SOT recipients; however, 2 recently published studies from
The United States\textsuperscript{104} and United Kingdom\textsuperscript{105} suggested that vaccinated SOT recipients have a reduced risk of developing symptomatic\textsuperscript{104} and lethal forms\textsuperscript{105} of SARS-CoV-2 infection compared with nonvaccinated SOT recipients. These preliminary results are encouraging but need validation. Moreover, correlation between immunogenicity in the use of antibody assays and neutralization platforms of vaccines and subsequent clinical protection needs further clarification to adapt our vaccine strategy in SOT recipients.

### CONCLUSIONS

KTRs infected with COVID-19 may have an increased risk of mortality compared with the general population and hemodialysis patients. Attributing this increased mortality to immunosuppression alone is imprudent, as a direct relationship has not been demonstrated so far. What is, however, clearly reported is that immunosuppression can reduce the humoral and cellular responses to vaccination; however, the interpretation of the data derived from the rapidly growing number of studies is complex because of the high heterogeneity in the use of antibody assays and neutralization platforms. Thus, until proven otherwise, immunosuppression reduction is a consideration in the early stages of infection. Handling immunosuppression in case of COVID-19 infection in KTRs should integrate the stage of infection, strength of immunosuppression, and comorbidities. Further studies will help clarify the implication of immunosuppressive drugs on KTRs’ outcomes. The relationship between immunogenicity of vaccines and subsequent clinical protection needs further clarification to adapt our vaccine strategy in SOT recipients. Finally, the combination of different preventive strategies (eg, vaccination and preventive monoclonal antibody infusion) should be tested in future clinical trials.

### REFERENCES

1. WHO coronavirus (COVID-19) dashboard. Retrieved November 30, 2021. Available at https://covid19.who.int. Accessed December 1, 2021.
2. Johns Hopkins University and Medicine. Coronavirus Resource Center. Mortality analyses. Retrieved November 30, 2021. Available at https://coronavirus.jhu.edu/data/mortality. Accessed December 1, 2021.
3. Raja MA, Mendoza MA, Villavicencio A, et al. COVID-19 in solid organ transplant recipients: a systematic review and meta-analysis of current literature. Transplant Rev (Orlando). 2021;35:100588.
4. Marinak Si, Tsiakas S, Korogiannou M, et al. A systematic review of COVID-19 infection in kidney transplant recipients: a universal effort to preserve patients’ lives and allografts. J Clin Med 2020;9:2986.
5. Kremer D, Pieters TT, Verhaar MC, et al. A systematic review and meta-analysis of COVID-19 in kidney transplant recipients: lessons to be learned. Am J Transplant. 2021;21:3936–3945.
6. Williamson EJ, Walker AJ, Bhaskaran K, et al. Factors associated with COVID-19-related death using OpenSAFELY. Nature. 2020;584:430–436.
7. Reilev M, Kristensen KB,Pottegård A, et al. Characteristics and predictors of hospitalization and death in the first 11 122 cases with a positive RT-PCR test for SARS-CoV-2 in Denmark: a nationwide cohort. Int J Epidemiol. 2020;49:1468–1481.
8. Bertrand D, Hamzaoui M, Lemée V, et al. Antibody and T cell response to SARS-CoV-2 messenger RNA BNT162b2 vaccine in kidney transplant recipients and hemodialysis patients. J Am Soc Nephrol. 2021;32:2147–2152.
9. Cucchiari D, Egri N, Bodro M, et al. Cellular and humoral response after MRNA-1273 SARS-CoV-2 vaccine in kidney transplant recipients. Am J Transplant. 2021;21:2727–2739.
10. Devresse A, Saad Albirchi I, Georghey H, et al. T-cell and antibody response after 2 doses of the BNT162b2 vaccine in a Belgian cohort of kidney transplant recipients. Transplantation. 2021;105:e142–e143.

---

**TABLE 4.**

| Publication | Study population | Vaccine | After 2 doses | After 3 doses | Risk factor impacting humoral response |
|-------------|------------------|---------|---------------|---------------|----------------------------------------|
| Cucchiari et al\textsuperscript{88} | 133 KTRs and kidney-pancreas transplant recipients | mRNA-1273 | 29.9%\textsuperscript{a} | | |
| Benotmane et al\textsuperscript{84} | 205 KTRs | mRNA-1273 | 48%\textsuperscript{a} | 49% of patients with no or low humoral response after 2 doses | - After 2 doses: Patients with a first KT, a longer time from transplantation, better kidney function, and less immunosuppression were more likely to seroconvert. |
| | | | | | - After 3 doses: Patients with no response after 2 doses (compared with those with weak response) and patients treated with and association of Tac–MPA–steroids (compared with other IS regimens) were less likely to respond. |
| | | | | | - The use of antimitobolite was associated with poor humoral response |
| Boyarsky et al\textsuperscript{85} | 658 SOT recipients | mRNA-1273 | 47% | 54%\textsuperscript{a} | |
| | | | | | - Patients who do not respond after 3 doses were older, had a higher degree of immunosuppression, and had lower graft function. |
| Kamar et al\textsuperscript{86} | 101 SOT recipients | BNT162b2 | 40%\textsuperscript{a} | 68% | |
| | | | | | - After 2 doses: The use of antimitobolite or steroids, older age, impaired kidney function, and KT ≤4 y were independent risk factors for nonresponse. |
| Masset et al\textsuperscript{87} | 456 KTRs and pancreas transplant recipients | BNT162b2 | 49.7%\textsuperscript{a} 69.2% | | |
| Hall et al\textsuperscript{88} | 60 KTRs | mRNA-1273 | 11%\textsuperscript{a} 55% | | |

\textsuperscript{a}Two weeks after the second dose. 
\textsuperscript{b}One month after the second dose.
\textsuperscript{c}Placebo-controlled randomized trial including 120 KTRs demonstrated that a booster third dose (n = 60) of the mRNA-1273 vaccine given 2 mo after the second dose was associated with higher rates of seroconversion, anti-RBD Ab titers, and virus neutralization 1 mo after injection compared with placebo (n = 60).

\textsuperscript{d}Two months after the second dose.
11. Mehta P, McAuley DF, Brown M, et al; HLH Across Speciality Collaboration, UK. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020;395:1033–1034.
12. Ruan Q, Yang K, Wang W, et al. Clinical predictors of mortality due to COVID-19 based on an analysis of data from 150 patients in Wuhan, China. Intensive Care Med. 2020;46:846–848.
13. Wu C, Chen X, Cai Y, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med. 2020;180:934–943.
14. Akalin E, Azzi Y, Bartash R, et al. COVID-19 and kidney transplantation. N Engl J Med. 2020;382:2475–2477.
15. Jager KJ, Kramer A, Chenxney NC, et al. Results from the ERA-EDTA Registry indicate a high mortality due to COVID-19 in dialysis patients and kidney transplant recipients across Europe. Kidney Int. 2020;98:1540–1548.
16. Cravedi P, Mothi SS, Azzi Y, et al. COVID-19 and kidney transplantation: results from the TANGO International Transplant Consortium. Am J Transplant. 2020;20:3140–3148.
17. Goffin E, Candelier A, Vart P, et al; ERA-EDTA Collaborators. COVID-19-related mortality in kidney transplant and haemodialysis patients: a comparative, prospective registry-based study. Nephrol Dial Transplant. 2021;36:2094–2105.
18. Chavarot N, Chavarot N, Francois H, et al; French SOT COVID Registry. COVID-19 infection: the perspectives on patients with Covid-19. N Engl J Med. 2021;384:693–704. Accessed December 1, 2021.
19. Hadi YB, Naqvi SFZ, Kupec JT, et al. Outcomes of COVID-19 in solid organ transplant patients. A propensity score-matched analysis of mortality in patients with Covid-19 infection 2019: results from the Brazilian multicenter cohort study. Clin Transplant. 2021;35:e14216.
20. Ritschl PV, Neevermann N, Wiering L, et al. Solid organ transplantation programs facing lack of empirical evidence in the COVID-19 pandemic: a By-proxy Society Recommendation Consensus approach. Am J Transplant. 2020;20:1826–1836.
21. Roberts MB, Fishman JA. Immunosuppressive agents and infectious disease. J Heart Lung Transplant. 2007;36:2562–2575.
22. Fisher AM, Schlauch D, Mullay M, et al. Outcomes of COVID-19 in hospitalised solid organ transplant recipients compared to a matched cohort of non-transplant patients at a national healthcare system in the United States. Transplantation. 2021;105:1221–1235.
23. Callebard S, Chavarot N, Francois H, et al; French SOT COVID Registry. Is COVID-19 infection more severe in kidney transplant recipients? Am J Transplant. 2021;21:1295–1303.
24. Siddiqi HK, Mehra MR. COVID-19 illness in native and immunosuppressed states: a clinical-therapeutic staging proposal. J Heart Lung Transplant. 2020;39:405–407.
25. Shi Y, Wang Y, Shao C, et al. COVID-19 infection: the perspectives on patients with Covid-19 infection 2019: results from the Brazilian multicenter cohort study. Clin Transplant. 2021;35:e14216.
26. Pfefferle S, Schöpf J, Kögl M, et al. The SARS-coronavirus-host interaction: identiﬁcation of cyclophilins as target for pari-coronavirus inhibitors. Plos Pathog. 2011;7:e1002331.
56. Carballo-Lozoya J, Müller MA, Kallies S, et al. Replication of human coronaviruses SARS-CoV, HCoV-NL63, and HCoV-229E is inhibited by the drug FK506. Virus Res. 2012;165:112–117.
57. Ma-Lauer Y, Zheng Y, Malešević M, et al. Influences of cyclosporin A and non-immunosuppressive derivatives on cellular cyclophilins and viral nucleocapsid protein during human coronavirus 229E replication. Antiviral Res. 2020;173:104620.
58. Shen L, Niu J, Wang C, et al. High-throughput screening and identification of potent broad-spectrum inhibitors of coronaviruses. J Virol. 2019;93:e00023–e00019.
59. Kato F, Matsuyama S, Kawase M, et al. Antiviral activities of mycophenolic acid and IMD-0354 against SARS-CoV-2. Microbiol Immunol. 2020;64:635–639.
60. Han Y, Yang L, Duan X, et al. Identification of candidate COVID-19 therapeutics using hFSC-derived lung organoids. bioRxiv. Preprint posted online May 5, 2020. doi:10.1101/2020.05.05.079095
61. Wullschleger S, Loewith R, Hall MN. TOR signaling in growth and metabolism. Cell. 2006;124:471–484.
62. Pascual J, Berger SP, Witzke O, et al; TRANSFORM Investigators. Erolimus with reduced calcineurin inhibitor exposure in renal transplantation. J Am Soc Nephrol. 2018;29:1979–1991.
63. Sommerer C, Suweland B, Dragun D, et al; Athena Study Group. An open-label, randomized trial indicates that everolimus with tacrolimus or cyclosporine is comparable to standard immunosuppression in de novo kidney transplant patients. Kidney Int. 2019;95:2341–2350.
64. Kindrachuk J, Ork B, Hart BJ, et al. Antiviral potential of ERK/MAPK or GM-CSF in COVID-19. Response to: ‘more evidences on which REgistry (SMACORE).
65. Kindrachuk J, Ork B, Hart BJ, et al. Antiviral potential of ERK/MAPK or GM-CSF in COVID-19. Response to: ‘more evidences on which REgistry (SMACORE).
66. Shin BH, Everly MJ, Zhang H, et al. Impact of tocilizumab (anti-IL-6R) treatment on immunoglobulins and anti-HLA antibodies in kidney transplant patients with chronic antibody-mediated rejection. Transplantation. 2020;104:e543.
67. Pottlebaum AA, Venkatachalum K, Liu C, et al. Efficacy and safety of tocilizumab in the treatment of acute active antibody-mediated rejection in kidney transplant recipients. Transplant Direct. 2020;6:e543.
68. Mosharnovabed H, Fatahy Y, Mobeabi H, et al. Tocilizumab in transpl. Eur J Clin Pharmacol. 2020;76:765–773.
69. Capra R, De Rossi N, Mattioli F, et al. Impact of low dose tocilizumab on mortality rate in patients with COVID-19 related pneumonia. Eur J Intern Med. 2020;76:31–35.
70. Klopfenstein T, Zayet S, Lohna A, et al; HNF Hospital Tocilizumab multidisciplinary team. Tocilizumab therapy reduced intensive care unit admissions and mortality in COVID-19 patients. Med Mal Infect. 2020;50:397–400.
71. Campochiaro C, Della-Torre E, Cavalli G, et al; TOCI-RAF Study Group. Efficacy and safety of tocilizumab in severe COVID-19 patients: a single-centre retrospective cohort study. Eur J Intern Med. 2020;76:43–49.
72. Colaneri M, Bogliolo L, Valsecchi P, et al. Tocilizumab for treatment of severe COVID-19 patients: preliminary results from SMAteo Covid19 Registry (SMACORE). Microorganisms. 2020;8:E695.
73. Dell'a Torre E, Campochiaro C, Cavalli G, et al. Targeting IL-1, IL-6 or GM-CSF in COVID-19. Response to: ‘more evidences on which biologic and which pathway is key in severe-critical COVID-19 pneumonia’ by Ferrariolli, Ann Rheum Dis. [Epub ahead of print. July 31, 2020], doi:10.1136/annrheumdis-2020-218612
74. Quarantucci J, Sonaglia A, McGregor D, et al; Profiling COVID-19 pneumonia progressing into the cytokine storm syndrome: results from a single Italian centre study on tocilizumab versus standard of care. J Clin Virol. 2020;129:104444.
75. Rojas-Marté G, Khalid M, Mukhtar O, et al. Outcomes in patients with severe COVID-19 disease treated with tocilizumab: a case-controlled study. QJM. 2020;113:546–550.
76. Palomino C, Vau C, et al. Tocilizumab in patients hospitalized with Covid-19 pneumonia. N Engl J Med. 2021;384:20–30.
77. Rossas IO, Brú O, Waters M, et al. Tocilizumab in hospitalized patients with severe Covid-19 pneumonia. N Engl J Med. 2021;384:1503–1516.
78. WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: a meta-analysis. JAMA. 2021;326:499–518.
79. Pereira MR, Aversa MM, Farra MA, et al. Tocilizumab for severe COVID-19 in solid organ transplant recipients: a matched cohort study. Am J Transplant. 2020;20:1320.
80. Kasiske BL, Zeier MG, Chapman JR, et al; Kidney Disease: Improving Global Outcomes. KDIGO clinical practice guideline for the care of kidney transplant recipients: a summary. Kidney Int. 2010;77:299–311.
81. Kim SJ, Rhiu J, Yoo H, et al. Outcome comparison between low-dose rabbit anti-thymocyte globulin and basiliximab in low-risk living donor kidney transplantation. J Clin Med. 2020;9:1320.
82. Avouac J, Drumez E, Hachulla E, et al; FAIR/SFR/SNFMI/SOFREMIP/ CRI/IMIDIATE consortium and contributors; FAIR/SFR/SNFMI/ SOFREMIP/CRI/IMIDIATE consortium and contributors. COVID-19 outcomes in patients with inflammatory rheumatic and musculoskeletal diseases treated with rituximab: a cohort study. Lancet Rheumatol. 2021;3:e419–e426.
83. Maroni M, Moulin E, Fafi-Kremer S, et al. First case of COVID-19 in a kidney transplant recipient treated with belatacept. Am J Transplant. 2020;20:1944–1946.
84. Benotmane I, Gaultier G, Perrin P, et al. Antibody response after a third dose of the mRNA-1273 SARS-CoV-2 vaccine in kidney transplant recipients with minimal serologic response to 2 doses. JAMA. 2021;326:1063–1065.
85. Boyarsky BJ, Wehrli WA, Avery RK, et al. Antibody response to 2-dose SARS-CoV-2 mRNA vaccine series in solid organ transplant recipients. JAMA. 2021;325:2204–2206.
86. Kamnar N, Abravanel F, Marion O, et al. Three doses of an mRNA Covid-19 vaccine in solid-organ transplant recipients. N Engl J Med. 2021;385:661–662.
87. Massel C, Kerleau C, Garancseau C, et al. A third injection of the BNT162b2 mRNA COVID-19 vaccine in kidney transplant recipients improves the humoral immune response. Kidney Int. 2021;100:1132–1135.
88. Hall VG, Ferreira VH, KU T, et al. Randomized trial of a third dose of mRNA-1273 vaccine in transplant recipients. N Engl J Med. 2021;385:1244–1246.
89. Benotmane I, Gaultier-Vargas G, Cognard N, et al. Low immunization rates among kidney transplant recipients who received 2 doses of the mRNA-1273 SARS-CoV-2 vaccine. Kidney Int. 2021;99:1498–1500.
90. Georgery H, Devresse A, Yombi JC, et al; Disappearing immunization rate after 2 doses of the BNT162b2 vaccine in a Belgian cohort of kidney transplant recipients. Transplantation. 2021;105:e283–e284.
91. Steensels D, Pierlet N, Penders J, et al. Comparison of SARS-CoV-2 antibody response following vaccination with BNT162b2 and mRNA-1273. JAMA. 2021;326:1533–1535.
92. Grupper A, Sharon N, Finn T, et al. Humoral response to the Pfizer BNT162b2 vaccine in patients undergoing maintenance hemodialysis. Clin J Am Soc Nephrol. 2021;16:1037–1042.
93. Labriola L, Scohy A, Van Regenmorter E, et al. Immunogenicity of BNT162b2 SARS-CoV-2 vaccine in a multicenter cohort of nursing home residents receiving maintenance hemodialysis. Am J Kidney Dis. 2021;78:766–768.
94. Georgery H, Devresse A, Yombi JC, et al. High response rate to BNT162b2 mRNA COVID-19 vaccine among self-care dialysis patients. Clin Kidney J. 2021;14:2129–2131.
95. Caillard S, Chavarot N, Bertrand F, et al; French Society of Rheumatology, CRI/IMIDIATE consortium and contributors; FAIR/SFR/SNFMI/ SOFREMIP/CRI/IMIDIATE consortium and contributors. COVID-19 outcomes in patients with inflammatory rheumatic and musculoskeletal diseases treated with rituximab: a cohort study. Lancet Rheumatol. 2021;3:e419–e426.
96. Chavarot N, Morel A, Leruez-Ville M, et al. Weak antibody response following vaccination with BNT162b2 and mRNA-1273 in solid organ transplant recipients. Transplantation. 2020;9:806.
100. Spiera R, Jinich S, Jannat-Khah D. Rituximab, but not other antirheumatic therapies, is associated with impaired serological response to SARS-CoV-2 vaccination in patients with rheumatic diseases. *Ann Rheum Dis.* 2021;80:1357–1359.

101. Bruchfeld A, Kronbichler A, Alberici F, et al. COVID-19 and ANCA-associated vasculitis: recommendations for vaccine preparedness and the use of rituximab. *Nephrol Dial Transplant.* 2021;36:1758–1760.

102. Willcocks LC, Chaudhry AN, Smith JC, et al. The effect of sirolimus therapy on vaccine responses in transplant recipients. *Am J Transplant.* 2007;7:2006–2011.

103. Struijk GH, Minnee RC, Koch SD, et al. Maintenance immunosuppressive therapy with everolimus preserves humoral immune responses. *Kidney Int.* 2010;78:934–940.

104. Aslam S, Adler E, Mekeel K, et al. Clinical effectiveness of COVID-19 vaccination in solid organ transplant recipients. *Transpl Infect Dis.* 2021;23:e13705.

105. Ravanan R, Mumford L, Ushiro-Lumb I, et al; OTDT Clinical Team. Two doses of SARS-CoV-2 vaccines reduce risk of death due to COVID-19 in solid organ transplant recipients: preliminary outcomes from a UK registry linkage analysis. *Transplantation.* 2021;105:e263–e264.